18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
18F-PD-L1 PET/CT to Predict Response to Nivolumab in Patients With NSCLC
Sponsor: Bristol-Myers Squibb
Listed as NCT03564197, this NA trial focuses on NSCLC Stage IV and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 15 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)18F-PD-L1 PET/CT scan to predict durable reponse to nivolumab containing treatment in patients with NSCLC
18F-PD-L1 PET/CT scan to predict durable reponse to nivolumab containing treatment in patients with NSCLC
Status Flow
Change History
15 versions recorded-
Feb 2026 — Present [monthly]
Completed NA
Status: Unknown → Completed
-
Nov 2025 — Feb 2026 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2025 — Nov 2025 [monthly]
Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 10 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Recruiting NA
-
Dec 2022 — Nov 2023 [monthly]
Recruiting NA
-
Feb 2021 — Dec 2022 [monthly]
Recruiting NA
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Jul 2020 — Jan 2021 [monthly]
Recruiting NA
-
Aug 2019 — Jul 2020 [monthly]
Recruiting NA
-
Jul 2019 — Aug 2019 [monthly]
Recruiting NA
Status: Active Not Recruiting → Recruiting
-
Dec 2018 — Jul 2019 [monthly]
Active Not Recruiting NA
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2018 — Dec 2018 [monthly]
Not Yet Recruiting NA
-
Jul 2018 — Sep 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- The Netherlands Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .